U.S. Markets closed

Biogen's blood disorder drug succeeds in late-stage trial

April 10 (Reuters) - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in maintaining low bleeding rates in children in a late-stage trial.

The drug, Eloctate, was being developed as a treatment for haemophilia A - a rare genetic disorder in which a person's blood does not clot properly due to missing or reduced levels of a particular protein.
